Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246496 | PMC |
| http://dx.doi.org/10.3389/falgy.2023.1214914 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Tumor microenvironment and beyond: imaging systemic immunity with PET.
Front Med (Lausanne)
December 2024
Preemptive Medicine and Lifestyle Related Disease Research Center, Kyoto University Hospital, Kyoto, Japan.
It Takes a Village! Navigating the Challenges and Opportunities in Immune-Related Adverse Event Management.
JCO Oncol Pract
December 2024
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Epigenetic regulation of complement C1Q gene expression.
Front Immunol
December 2024
Department of Life Sciences, University of Trieste, Trieste, ;Italy.
Human C1q is a multifaceted complement protein whose functions range from activating the complement classical pathway to immunomodulation and promoting placental development and tumorigenesis. It is encoded by the , , and genes located on chromosome 1. C1q, unlike most complement components, has extrahepatic expression by a range of cells including macrophages, monocytes and immature dendritic cells.
View Article and Find Full Text PDFA blood-based mRNA signature distinguishes people with Long COVID from recovered individuals.
Front Immunol
December 2024
Department of Microbiology, Anatomy, Physiology and Pharmacology, La Trobe University, Bundoora, VIC, Australia.
Introduction: Long COVID is a debilitating condition that lasts for more than three months post-infection by SARS-CoV-2. On average, one in ten individuals infected with SARS CoV- 2 develops Long COVID worldwide. A knowledge gap exists in our understanding of the mechanisms, genetic risk factors, and biomarkers that could be associated with Long COVID.
View Article and Find Full Text PDFCytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors.
World J Clin Cases
December 2024
Laboratorio de Psicoinmunología, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 11340, Mexico.
In recent years, cancer immunotherapy has introduced novel treatments, such as monoclonal antibodies, which have facilitated targeted therapies against tumor cells. Programmed death-1 (PD-1) is an immune checkpoint expressed in T cells that regulates the immune system's activity to prevent over-activation and tissue damage caused by inflammation. However, PD-1 is also expressed in tumor cells and functions as an immune evasion mechanism, making it a therapeutic target to enhance the immune response and eliminate tumor cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!